Isabelle Riviere
Direktor/Vorstandsmitglied bei Centre For Commercialization of Cancer Immunotherapy
Profil
Isabelle Riviere is the founder of Juno Therapeutics, Inc. which was founded in 2013.
Currently, she holds the position of Director at the Centre For Commercialization of Cancer Immunotherapy.
Aktive Positionen von Isabelle Riviere
| Unternehmen | Position | Beginn |
|---|---|---|
Centre For Commercialization of Cancer Immunotherapy
 Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Isabelle Riviere
| Unternehmen | Position | Ende |
|---|---|---|
| JUNO THERAPEUTICS INC | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Centre For Commercialization of Cancer Immunotherapy
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. |
